(Reuters) - Amgen also said the U.S. Senate Finance Committee sent a letter to the company on May 16 requesting a briefing to discuss the issues and concerns reported in the media related to the marketing and safety of erythropoiesis stimulating agents.
Read more at Reuters.com Government Filings News
Read more at Reuters.com Government Filings News
No comments:
Post a Comment